<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05107193</url>
  </required_header>
  <id_info>
    <org_study_id>1200-0344</org_study_id>
    <nct_id>NCT05107193</nct_id>
  </id_info>
  <brief_title>Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors)</brief_title>
  <official_title>Assessment of Prospective Real-world Outcomes Based on Single-patient Protocol Data Collection of Afatinib (GILOTRIF®) Use in Patients With Solid Tumors Harboring NRG1 Gene Fusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Gene fusions are defined as two separate genes joined together (gene 1, gene 2), generating a&#xD;
      novel fusion gene. NRG1 fusions are rare and complex with regard to the fusion/fusion&#xD;
      partner. The specific NRG1 gene fusion will be identified by a specialized molecular testing&#xD;
      lab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Afatinib is provided on a single-patient protocol basis to patients suffering from tumors&#xD;
      harboring NRG1 fusions, a disease for which no satisfactory authorised alternative therapy&#xD;
      exists.&#xD;
&#xD;
      In the context of this mechanism it is planned to collect and analyze limited clinical data&#xD;
      in order to investigate the safety and efficacy of afatinib in patients with advanced and/or&#xD;
      metastatic solid tumours harboring NRG1 gene fusions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Solid Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>afatinib</intervention_name>
    <description>afatinib</description>
    <other_name>GILOTRIF®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria to participate in this program:&#xD;
&#xD;
          -  Confirmed diagnosis of an advanced, unresectable and/or metastatic tumor harboring&#xD;
             NRG1 gene fusions characterized as follows:&#xD;
&#xD;
               -  Gene 1: NRG1 (prerequisite: conservation of the epidermal growth factor (EGF) -&#xD;
                  this will be identified by the lab performing the molecular testing)&#xD;
&#xD;
               -  Gene 2: All fusion partners are allowed (prerequisite: the region must be a&#xD;
                  coding region - this will be identified by the lab performing the molecular&#xD;
                  testing)&#xD;
&#xD;
          -  Patient must have measurable or evaluable lesions (according to RECIST 1.1).&#xD;
&#xD;
          -  At least 18 years of age at the time of consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with a systemic anti-cancer therapy or investigational drug within 14 days&#xD;
             or 5 half-lives (whichever is shorter) of the first treatment with the study&#xD;
             medication.&#xD;
&#xD;
          -  Tumors carrying additional gene mutations in the Kirsten Rat Sarcoma Viral Oncogene&#xD;
             Homolog (KRAS) and/or Epidermal Growth Factor Receptor (EGFR) genes&#xD;
&#xD;
          -  Prior treatment with a therapy targeting erythroblastic leukemia viral oncogene&#xD;
             homologue receptors (ErbB)&#xD;
&#xD;
          -  Any patient considered ineligible by the treating physician.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NRG1 fusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Afatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

